Efavirenz Tablets
developed to manage hiv-1 infection indicated to target viral replication.
Strengths: 200 · 600mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Sustiva
- Therapeutic class
Non-nucleoside Reverse Transcriptase Inhibitor
- Pharmacological class
NNRTI
- Contraindications
hypersensitivity; severe hepatic impairment; concurrent use of St. John's wort
- Minor side effects
dizziness; rash; fatigue
- Moderate side effects
insomnia; abnormal dreams; impaired concentration
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Patient summary
developed to manage hiv-1 infection indicated to target viral replication.
- Prescription status
POM
- Manufacturer
Bristol-Myers Squibb
- Onset Time
3–5 hours
- Duration
24 hours
- Storage instructions
Store at room temperature in a tightly closed container.
- Drug interactions
St. John's wort; midazolam; voriconazole
- Age restrictions
Adjust dosage by weight for children as directed by a specialist.
- Pregnancy and breastfeeding
Contraception required during treatment due to potential foetal harm.
Precautions and warnings
monitor for psychiatric or nerve system symptoms; maintain consistent adherence to avoid drug resistance
Serious side effects
severe psychiatric symptoms — requires immediate medical attention; hepatotoxicity — requires immediate medical attention
Mechanism of action
Efavirenz is a non-nucleoside reverse transcriptase inhibitor that binds directly to the HIV-1 reverse transcriptase enzyme, blocking RNA-dependent and DNA-dependent polymerase activity and preventing viral DNA synthesis.
Efavirenz Tablets
developed to manage hiv-1 infection indicated to target viral replication.
Editorial Notes
- Active ingredient(s): Efavirenz
- Listed indication(s): HIV Infection
Usually available as
- 30 tablets - 200 mg1375-200-mg-16505
- 10 tablets - 600 mg1375-600-mg-16509